Crohn's Disease Diagnostic And Therapeutic Market Size and Forecast 2032

Crohn's Disease Diagnostic And Therapeutic Market Overview:

The global Crohns Disease Diagnostic And Therapeutic Market size was estimated at USD 12,486.39 million in 2025 and is expected to reach USD 19,421.33 million by 2032, growing at a CAGR of 7.64% from 2025 to 2032. Demand is being shaped by wider use of advanced therapies for moderate-to-severe disease, with treatment strategies increasingly oriented toward sustained inflammation control and relapse prevention. Market momentum is also supported by more structured monitoring across the disease course, which reinforces repeat utilization across diagnostic modalities and long-term maintenance regimens.

Key Market Trends & Insights

• The market is projected to expand from USD 12,486.39 million in 2025 to USD 19,421.33 million by 2032, reflecting a 7.64% CAGR for 2025–2032.
• Anti-TNF accounted for the largest share of 34.2% in 2025 within the therapy class landscape, supported by entrenched prescribing and broad clinical familiarity.
• North America represented 43.1% of 2025 revenue, reflecting strong specialist access, early diagnosis pathways, and high utilization of advanced therapies.
• Europe contributed 28.4% of 2025 revenue, supported by mature IBD care pathways and sustained biologic and diagnostic utilization in major markets.
• Asia Pacific held 20.2% of 2025 revenue, with expanding diagnosis capacity and increasing uptake of advanced therapies in higher-access markets.

Segment Analysis

Crohns disease care is increasingly managed as a long-horizon condition that requires both effective induction and durable maintenance, which expands the long-term footprint of therapeutics and follow-up diagnostics. A sustained shift toward biologics is evident in real-world utilization, reflecting clinical preference for deeper control of inflammation and improved long-term outcomes in appropriate patient segments. At the same time, ongoing monitoring requirements reinforce recurring demand for endoscopy, imaging, and biomarker testing, particularly as treat-to-target practices become more embedded in specialist workflows.

The market’s segment dynamics also reflect trade-offs among efficacy expectations, safety monitoring, administration convenience, and payer-driven step therapy. IV and SC modalities remain critical because many advanced therapies and escalation pathways are delivered through infusion or injection channels, supporting recurring utilization tied to maintenance and monitoring schedules. Diagnostics remain integral across diagnosis confirmation, staging, and relapse assessment, shaping continuous demand beyond initial workups.

By Product Type Insights

Biologics remain central to the therapeutic mix because treatment goals increasingly prioritize sustained remission and reduced complication risk in moderate-to-severe disease. Immunosuppressants continue to play roles in select regimens, including combination strategies and cost-sensitive settings, though utilization is often shaped by safety monitoring needs and evolving practice patterns. Diagnostics remain a core component of the overall market because confirmation, staging, and ongoing monitoring are required across the disease lifecycle. The balance across product types is influenced by guideline practices, payer controls, and the availability of advanced therapies and monitoring infrastructure.

By Therapy Class Insights

Anti-TNF accounted for the largest share of 34.2% in 2025. Broad clinical experience, established prescribing pathways, and extensive real-world evidence support continued use across induction and maintenance strategies. Anti-TNF options also benefit from clear positioning in many treatment algorithms and consistent outcomes expectations in appropriately selected patients. IL inhibitors are expanding options and influencing switching dynamics, but anti-TNF remains a frequent anchor therapy in many lines of care.

By Diagnostic Type Insights

Endoscopy plays a central role in confirming diagnosis and assessing mucosal inflammation, supporting its routine use in specialist pathways. Imaging remains important for evaluating small bowel involvement and complications, particularly in complex disease presentations. Biomarkers support less invasive monitoring and triage, complementing endoscopy and imaging in longitudinal management. Diagnostic choice is influenced by disease activity, care setting capabilities, and clinician preference for balancing invasiveness, cost, and information yield.

By Treatment Stage Insights

Induction demand is supported by the need for rapid symptom control and early inflammation suppression in active disease, particularly in moderate-to-severe presentations. Maintenance expands as more patients remain on long-term advanced therapies to reduce relapse risk and avoid complications. Treatment optimization and switching can increase utilization across both stages, especially when response durability varies by patient segment. Monitoring intensity and treat-to-target adoption reinforce sustained maintenance planning and follow-up testing.

By Administration Route Insights

IV administration remains important because induction regimens and several advanced therapies are delivered through infusion-based care pathways. SC options expand flexibility for maintenance and improve convenience in eligible patients, supporting broader outpatient utilization where health systems support training and adherence. Oral options can strengthen uptake where convenience is prioritized, but use is influenced by safety monitoring, payer positioning, and line-of-therapy policies. Route selection is shaped by clinical severity, prior treatment exposure, and patient preference.

Crohn's Disease Diagnostic And Therapeutic Market Drivers

Expansion of advanced therapy utilization in moderate-to-severe disease

Crohns Disease Diagnostic And Therapeutic Market growth is supported by rising utilization of advanced therapies that target inflammatory pathways more precisely. Specialist care increasingly emphasizes early control of inflammation to reduce complications and hospitalization risk. This approach can intensify the use of induction regimens and extend time on maintenance therapies. Wider clinician familiarity with advanced regimens also supports adoption across more treatment settings and eligible patient groups.

Treat-to-target practices strengthening diagnostic and monitoring intensity

Crohns Disease Diagnostic And Therapeutic Market growth is driven by care models that prioritize objective measures of disease control rather than symptom-only management. Treat-to-target approaches reinforce repeat use of endoscopy, imaging, and biomarker testing to guide therapy optimization. Monitoring-driven decision-making supports earlier escalation when control is inadequate and supports maintenance decisions when remission is achieved. This dynamic increases repeat testing volumes across the disease lifecycle.

• For instance, BÜHLMANN reported that its IBDoc home fecal calprotectin platform showed a correlation coefficient of 0.887 versus the laboratory BÜHLMANN fCAL turbo assay, and a UK study cited by the company found that use of IBDoc after anti-TNF induction saved 53 clinical visits and 62 colonoscopies.

Site-of-care flexibility and administration innovation

Crohns Disease Diagnostic And Therapeutic Market growth is supported by ongoing shifts toward more flexible administration options that can reduce reliance on facility-based infusion in appropriate patients. Expanded SC maintenance options can support adherence and improve patient convenience, particularly in long-term therapy use. These shifts can also influence payer and provider preferences by changing cost and utilization patterns across hospital, infusion center, and outpatient settings. Greater route flexibility strengthens competitive differentiation among major brands.

Improving diagnosis rates and structured specialty referral

Crohns Disease Diagnostic And Therapeutic Market growth is supported by improving recognition of inflammatory bowel disease and more structured referral into specialist care pathways. Increased access to diagnostic infrastructure in large urban centers and major health systems supports earlier confirmation and staging. Earlier diagnosis typically increases the duration of active monitoring and longitudinal treatment. These patterns expand demand across both diagnostic and therapeutic components of the market.

• For instance, Medtronic’s PillCam Crohn’s Capsule was used in a multicentre pilot study that developed an AI model from 8,085 capsule images, including 2,855 ulcer images and 1,975 erosion images, and the model delivered 90.0% sensitivity, 96.0% specificity, 97.1% precision, and 92.4% accuracy for lesion detection, demonstrating how advanced diagnostic technology can strengthen earlier identification and assessment of Crohn’s disease extent.

Crohn's Disease Diagnostic And Therapeutic Market Challenges

Crohns Disease Diagnostic And Therapeutic Market faces challenges tied to cost pressure and payer controls that can limit the speed and breadth of advanced therapy uptake. Step therapy requirements, prior authorizations, and formulary restrictions can delay therapy initiation and influence switching patterns across brands. Operational complexity also remains a constraint, particularly when monitoring requirements and administration logistics burden clinics and patients. These factors can reduce adherence and create variability in real-world persistence.

• For instance, Takeda’s Phase 3 VISIBLE 2 study randomized 409 Crohn’s disease patients, and its subcutaneous ENTYVIO 108 mg maintenance regimen given every 2 weeks achieved clinical remission in 48% of patients at Week 52 versus 34% with placebo, while also introducing a prefilled pen option designed for at-home administration, underscoring how route-of-administration innovation can improve convenience but still leave monitoring, access, and payer management as practical barriers to persistence.

Crohns Disease Diagnostic And Therapeutic Market also contends with clinical heterogeneity and variable treatment response, which can raise trial-and-error switching and increase monitoring load. Safety considerations and patient-specific risk profiles may restrict therapy eligibility, especially for immune-modulating regimens. Capacity constraints in specialist services can slow diagnosis confirmation and escalation in some settings. These pressures are more visible in regions with uneven access to gastroenterology specialists and advanced diagnostic tools.

Crohn's Disease Diagnostic And Therapeutic Market Trends and Opportunities

Crohns Disease Diagnostic And Therapeutic Market is seeing continued momentum toward differentiated mechanisms and therapy sequencing strategies that improve durability of response. Increased use of combination and optimization strategies creates opportunity for solutions that support monitoring, adherence, and personalized escalation. Growth in SC and outpatient-friendly regimens expands opportunities for care models that reduce time in infusion settings. These shifts can improve patient convenience and increase persistence where system support is strong.

• For instance, AbbVie reported in its Phase 3 AFFIRM study that subcutaneous risankizumab achieved Crohn’s Disease Activity Index clinical remission in 55% of patients versus 30% with placebo and endoscopic response in 44% versus 14% at week 12; among responders who continued through week 24, 67% achieved clinical remission and 57% achieved endoscopic response, highlighting how SC delivery can support therapy sequencing and outpatient management.

Crohns Disease Diagnostic And Therapeutic Market opportunities are also expanding in noninvasive monitoring and workflow integration that improve longitudinal disease management. Biomarker adoption can support triage and reduce unnecessary invasive procedures when paired with clinical decision pathways. Improved access to diagnostics across emerging markets can expand earlier detection and structured follow-up. Opportunities are strongest where health systems invest in specialty capacity and standardized care pathways.

Regional Insights

North America

North America held 43.1% share in 2025, supported by strong specialist density, mature diagnostic pathways, and high utilization of advanced therapies for moderate-to-severe disease. Hospital systems and large GI networks often standardize care pathways that reinforce consistent monitoring across the disease lifecycle. Payer policy influences therapy sequencing, but advanced treatments remain widely used in eligible patients. Long-term maintenance adoption supports recurring utilization across both therapeutics and monitoring.

Europe

Europe accounted for 28.4% share in 2025, supported by structured care pathways and sustained adoption of biologic and targeted therapies in major markets. Providers often emphasize outcomes consistency, safety monitoring, and guideline-aligned escalation, reinforcing demand across maintenance and diagnostics. Procurement and reimbursement structures can shape therapy mix and switching decisions across branded and biosimilar options. Diagnostic intensity remains strong in specialist centers, supporting repeat utilization.

Asia Pacific

Asia Pacific represented 20.2% share in 2025, supported by expanding diagnosis capacity and growing adoption of advanced therapies in developed and higher-access markets. Urban centers continue to increase specialist availability and diagnostic infrastructure, improving detection and follow-up management. Therapy adoption is influenced by reimbursement expansion, private channel availability, and the presence of international clinical practice influence in leading hospitals. Market expansion is reinforced by improving continuity of care and increasing specialist-driven monitoring.

Latin America

Latin America held 5.6% share in 2025, with demand shaped by expansion of specialty care in major cities and gradual increases in access to advanced therapies. Market uptake is influenced by reimbursement variability and uneven access to infusion and monitoring infrastructure outside large centers. Private channels and high-complexity hospitals often lead adoption of advanced therapeutics and repeat monitoring. Distribution strength and local access programs can meaningfully affect market penetration.

Middle East & Africa

Middle East & Africa represented 2.7% share in 2025, with utilization concentrated in higher-access urban systems and select Gulf markets. Diagnostic access and specialist availability vary widely across the region, shaping differences in detection and long-term follow-up intensity. Advanced therapy access can be limited by reimbursement depth and supply constraints in lower-access settings. Growth opportunities are linked to expanding specialty infrastructure and improved continuity in chronic disease management.

Competitive Landscape

Crohns Disease Diagnostic And Therapeutic Market competition is driven by portfolio breadth across induction and maintenance needs, differentiation through mechanism and route-of-administration flexibility, and payer positioning that influences sequencing. Companies compete on clinical performance expectations, safety profiles, convenience, and patient support programs that reinforce adherence and persistence. Differentiation is also supported by evidence generation in real-world settings and the ability to support standardized protocols in large health systems. Competitive pressure from biosimilars can reshape pricing and switching dynamics while maintaining high treatment volumes.

AbbVie remains a key competitor through focus on advanced therapies and continued evidence generation across inflammatory bowel disease care pathways. Product strategy emphasizes expanding clinical options that support durable disease control and convenient administration for eligible patients. Commercial execution benefits from established presence in immunology and relationships with specialist prescribers. Ongoing clinical progress and label evolution can influence therapy sequencing and new-start dynamics in moderate-to-severe disease.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie
• Johnson & Johnson
• Pfizer
• Takeda
• Roche
• Amgen
• BMS
• Eli Lilly
• Merck & Co.
• Ferring

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Developments

• In January 2025, Eli Lilly announced that the U.S. FDA approved Omvoh (mirikizumab-mrkz) for adults with moderately to severely active Crohn’s disease, making it an important new therapeutic launch in this market.
• In March 2025, Johnson & Johnson received FDA approval for Tremfya (guselkumab) for adults with moderately to severely active Crohn’s disease, expanding its immunology portfolio into this indication.
• In May 2025, ALPCO announced the European commercial launch of its Calprotectin Immunoturbidimetric Assay, a diagnostic product designed to support inflammatory bowel disease testing, including Crohn’s disease.
• In July 2024, Sandoz launched Pyzchiva (ustekinumab) across Europe, introducing the first ustekinumab biosimilar there with all reference medicine strengths, including the 130 mg initiation dose relevant to Crohn’s disease treatment.

Report Scope

Segmentation

By Product Type

• Biologics
• Immunosuppressants
• Diagnostics

By Therapy Class

• Anti-TNF
• IL Inhibitors

By Diagnostic Type

• Imaging
• Biomarkers
• Endoscopy

By Treatment Stage

• Induction
• Maintenance

By Administration Route

• IV
• SC
• Oral

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.